Genta, AVI BioPharma, Invitrogen, and the Strategic Research Institute | GenomeWeb

Genta Says Aventis Takeover Won’t Change Terms of Genasense Deal

Genta said this week that its deal with French drug maker Aventis for the investigational antisense cancer drug Genasense includes a provision under which the partnership will be assigned to a successor in the event of a change of control at Aventis. The statement comes amid a recent $60 billion hostile takeover offer for drug maker Aventis by peer Sanofi-Synthelabo.

Aventis bought the rights to Genasense from Genta in 2002.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.